explore -WSS

explore

author：knowledge 2025-09-29 21:27:06 - browse：6

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： WATCH: Why do bright lights make us see spots?

leisure time

WSS

White House touts steps to stem shortages of cancer treatments

Stories you might have missed in 2023: health, science, medicine

Popular nasal decongestant doesn't actually relieve congestion

Acelyrin, a rare IPO success, stumbles in its first big test

At JPM 2024, hospital systems pitch financial strength to investors

Nonprofit, backed by Microsoft, to certify AI tools in health care

Wikipedia

explore

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Does Paxlovid work in people vaccinated against Covid

Malaria cases in Florida and Texas: Here’s what you need to know

New Covid vaccine is recommended for everyone 6 months or older

Bright Health sells Medicare Advantage business to Molina

Merck to acquire Harpoon Therapeutics for $680 million

Apple is now the first public company to be valued at $3 trillion

JPM pitch from hospitals? Revenue streams outside of patient care

After affirmative action ruling, medical educators look to 'holistic review'

A common UTI test for kids haunts adults as a traumatic 'nightmare'

explore

A preacher's new calling: Diversifying neuroscience research

Life science postdocs should get big pay hike, NIH panel says

Private equity could exacerbate cardiology's overuse problem, experts fear

Nonprofit, backed by Microsoft, to certify AI tools in health care

Profiling embryos to choose those with higher IQs is almost a reality

STAT Virtual Event: JPM Recap, Live!

entertainment

Wikipedia

leisure time

leisure time